WOCKPHARMA2023-04-012023-06-30 WOCKPHARMA2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member WOCKPHARMA2023-04-012023-06-30in-bse-fin:OneOperatingExpenses02Member WOCKPHARMA2023-06-30 WOCKPHARMA2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member WOCKPHARMA2023-04-012023-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532300 WOCKPHARMA NA Wockhardt Limited Equity 2023-04-01 2024-03-31 2023-08-14 2023-08-04 INR Crores First quarter 11:45:00 14:00:00 2023-08-14 2023-08-14 Not applicable Single segment Pharmaceuticals 2023-04-01 2023-06-30 Unaudited Consolidated 6440000000.00 140000000.00 6580000000.00 1370000000.00 1500000000.00 -50000000.00 1540000000.00 790000000.00 550000000.00 1920000000.00 7620000000.00 -1040000000.00 -140000000.00 -1180000000.00 90000000.00 90000000.00 180000000.00 0.00 -1360000000.00 0.00 0.00 0.00 0.00 -1360000000.00 -10000000.00 -1370000000.00 -1340000000.00 -20000000.00 -1340000000.00 -30000000.00 720000000.00 5 -9.28 -9.28 0.00 0.00 -9.28 -9.28 0.00 0.00 0.00 Notes To Consolidated Results:- 1. The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 14, 2023. The results have been subjected to limited review by the Statutory Auditors of the Company. 2. The Consolidated Results relate to Wockhardt Limited ('the Company' or 'the Holding Company') and its Subsidiaries (together constitute ‘the Group’) and are prepared by applying Ind AS 110 - Consolidated Financial Statements . 3. During the previous year and quarter ended March 31, 2023, subsequent to the settlement agreement with the State of Texas on February 8, 2022, the Group had agreed for an early payment schedule for the settlement of the liability. Pursuant to this revision, Group had recorded an additional cost of Rs.11 crores due to unwinding of the discount (basis the original payment schedule) and has disclosed this as 'Exceptional items'. 4. During the previous year ended March 31, 2023, the Group has provided/ incurred loss of Rs. 123 crores w.r.t property , plant and equipment sold/ held for sale, Rs. 17 crores for inventory, Rs. 80 crores for claims incurred/ expected claims from customers and Rs. 13 crores for other costs pursuant to the restructuring of business in USA and has disclosed these as 'Exceptional items'. The impact of the above matters for the quarter ended March 31, 2023 was Rs. 85 crores 5. The Company had accounted for a contract asset of Rs. 50 crores pursuant to a contract manufacturing agreement The Customer is yet to fulfill its contractual obligations and commitments. Though, the Company is pursuing various options and taking necessary actions related to this matter, given the uncertainty, the Company had provided for this contract asset in the previous year and this was disclosed as 'Exceptional items'. The Company had also purchased certain specific inventory for this contract which has not been used. The Company is continuing to evaluate alternate options to liquidate/ utilize such inventory, pending which, during the current quarter, the Company has made a provision of Rs. 14 crores for such inventory basis the current assessment and information available as on date. This expenditure is also reported as ‘Exceptional items’. 6. During the quarter ended June 30 2023, the Company has allotted 6,250 Equity shares of face value of Rs. 5 each pursuant to exercise of employee stock options. 7. Key Financials on Standalone basis: (Rs. in Crore) PARTICULARS 3 MONTHS ENDED 30/06/2023 3 MONTHS ENDED 31/03/2023 3 MONTHS ENDED 30/06/2022 YEAR ENDED 31/03/2023 Unaudited Audited Unaudited Audited Total Income 257 320 290 1,139 Loss before tax (115) (289) (54) (513) Loss after tax (115) (299) (37) (466) Note: The unaudited standalone results have been filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchanges websites (www.nseindia.com and www.bseindia.com ) and also on the Company's website www.wockhardt.com. 8. Figures for the quarter ended March 31, 2023 are the balancing figures between the audited figures of the full financial year and the reviewed figures upto the third quarter of financial year 2022-23. 9. The Group is exclusively into Pharmaceutical business Segment. 10. For List of Subsidiaries as on June 30, 2023 please refer Annexure. Exchange Fluctuation loss,net 20000000.00 Other expenses 1900000000.00 Items that will not be reclassified to Profit or Loss -(charge) / credit (consisting of re-measurement of net defined benefit (liability) / asset) 10000000.00 Income tax relating to items that will not be reclassified to Profit or Loss -credit/(charge) 0.00 10000000.00 0.00 Items that will be reclassified to Profit or Loss - (charge) / credit (Consisting of Exchange differences on translating the financial statements of foreign operations) (Continued operations) -20000000.00 -20000000.00 0.00